{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:34:08Z","timestamp":1762900448467},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,5]]},"DOI":"10.7759\/cureus.38582","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T12:51:59Z","timestamp":1683291119000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan"],"prefix":"10.7759","author":[{"given":"Aswanth","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nkolika","family":"Nwankwo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aswini","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel RL","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020, 70:7-30. 10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","unstructured":"Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012, 487.330-7. 10.1038\/nature11252","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30097","article-title":"Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis","volume":"3","author":"Kasi A","year":"2020","unstructured":"Kasi A, Abbasi S, Handa S, Al-Rajabi R, Saeed A, Baranda J, Sun W. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020, 3:e2030097. 10.1001\/jamanetworkopen.2020.30097","journal-title":"JAMA Netw Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie YH","year":"2020","unstructured":"Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020, 5:22. 10.1038\/s41392-020-0116-z","journal-title":"Signal Transduct Target Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser MM","year":"2007","unstructured":"Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007, 26:6469-87. 10.1038\/sj.onc.1210477","journal-title":"Oncogene"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/path.4679","article-title":"HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials","volume":"238","author":"Richman SD","year":"2016","unstructured":"Richman SD, Southward K, Chambers P, et al.. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016, 238:562-70. 10.1002\/path.4679","journal-title":"J Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00226","article-title":"Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer","volume":"3","author":"Raghav K","year":"2019","unstructured":"Raghav K, Loree JM, Morris JS, et al.. Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis Oncol. 2019, 3:1-13. 10.1200\/PO.18.00226","journal-title":"JCO Precis Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.98","article-title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","volume":"28","author":"Valtorta E","year":"2015","unstructured":"Valtorta E, Martino C, Sartore-Bianchi A, et al.. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015, 28:1481-91. 10.1038\/modpathol.2015.98","journal-title":"Mod Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/12.suppl_1.S9","article-title":"The role of overexpressed HER2 in transformation","volume":"12","author":"Neve RM","unstructured":"Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Annals of oncology. 12:9-13. 10.1093\/annonc\/12.suppl_1.S9","journal-title":"Annals of oncology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam F","year":"2019","unstructured":"Meric-Bernstam F, Hurwitz H, Raghav KP, et al.. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019, 20:518-30. 10.1016\/S1470-2045(18)30904-5","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2020.06.009","article-title":"Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer","volume":"19","author":"Tosi F","year":"2020","unstructured":"Tosi F, Sartore-Bianchi A, Lonardi S, et al.. Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin Colorectal Cancer. 2020, 19:256-262.e2. 10.1016\/j.clcc.2020.06.009","journal-title":"Clin Colorectal Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial","volume":"5","author":"Sartore-Bianchi A","year":"2020","unstructured":"Sartore-Bianchi A, Lonardi S, Martino C, et al.. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open. 2020, 5:e000911. 10.1136\/esmoopen-2020-000911","journal-title":"ESMO Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00306","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR study","volume":"6","author":"Gupta R","year":"2022","unstructured":"Gupta R, Meric-Bernstam F, Rothe M, et al.. Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR study. JCO Precis Oncol. 2022, 6:e2200306. 10.1200\/PO.22.00306","journal-title":"JCO Precis Oncol"},{"key":"ref14","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)","volume":"35","author":"Yoshino T","year":"2021","unstructured":"Yoshino T, Di Bartolomeo M, Raghav KS, et al.. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). J Clin Oncol. 2021, 35:3505.","journal-title":"J Clin Oncol"},{"key":"ref15","unstructured":"FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer. (2023). Accessed. April 20, 2023: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tucatinib-trastuzumab-...."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.7023","article-title":"Response to trastuzumab and lapatinib in a metastatic colorectal cancer harboring HER2 amplification and HER2 S310F mutation","volume":"19","author":"Wang C","year":"2021","unstructured":"Wang C, Fakih M. Response to trastuzumab and lapatinib in a metastatic colorectal cancer harboring HER2 amplification and HER2 S310F mutation. J Natl Compr Canc Netw. 2021, 19:670-4. 10.6004\/jnccn.2021.7023","journal-title":"J Natl Compr Canc Netw"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.9.8.11881","article-title":"Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib","volume":"9","author":"Xu Y","year":"2010","unstructured":"Xu Y, Liu H, Chen J, Zhou Q. Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol Ther. 2010, 9:572-82. 10.4161\/cbt.9.8.11881","journal-title":"Cancer Biol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/154268-a-case-of-her2-mutated-colorectal-cancer-treated-successfully-with-fam-trastuzumab-deruxtecan","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:34Z","timestamp":1707508654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/154268-a-case-of-her2-mutated-colorectal-cancer-treated-successfully-with-fam-trastuzumab-deruxtecan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.38582","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,5]]}}}